| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/19/2006 | US20060013800 Stable immunogenic product comprising antigenic heterocomplexes |
| 01/19/2006 | US20060013794 Cosmetic or pharmaceutical composition comprising peptides with the sequences arggly-ser |
| 01/19/2006 | US20060013782 Use of active extracts to improve the appearance of skin, lips, hair and/or nails |
| 01/19/2006 | US20060013776 Methods and compositions for treating benign gynecological disorders |
| 01/19/2006 | DE10247755B4 Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine Selective, local activation of members of the TNF receptor family by systemically inactive non-antibody-TNF-ligand fusion proteins |
| 01/19/2006 | CA2577332A1 Combination therapy for the prevention or treatment of alzheimer's disease as well as kit therefor |
| 01/19/2006 | CA2575278A1 Epidermal growth factor receptor antagonists and methods of use |
| 01/19/2006 | CA2573596A1 S100 protein inhibitors for treating leukemia |
| 01/19/2006 | CA2573441A1 Use of botulinum toxin for the preparation of a medicament for the treatment of lithiasis of salivary gland, gall bladder, kidney, or pancreas |
| 01/19/2006 | CA2573424A1 Method for preventing and treating alzheimer´s disease |
| 01/19/2006 | CA2573400A1 Cyclosporins to treat alzheimer's disease |
| 01/19/2006 | CA2573377A1 Reagents for diagnosis and therapy of latex allergy and method for the preparation of the same |
| 01/19/2006 | CA2573309A1 Transmucosal administration agent containing pth |
| 01/19/2006 | CA2573261A1 Compositions for enhancing the production of ppar and/or ppar-associated factors |
| 01/19/2006 | CA2572984A1 A pharmaceutical composition containing polypeptide fragments of the serralysins |
| 01/19/2006 | CA2572915A1 Pharmaceutical composition containing botulinum neurotoxin |
| 01/19/2006 | CA2572895A1 Compositions and methods for dermatological wound healing |
| 01/19/2006 | CA2572873A1 Inhibitors based on fusion, hr1 and hr2 sequences in bacterial adhesin |
| 01/19/2006 | CA2570396A1 Antibacterial peptides and analogues thereof |
| 01/19/2006 | CA2570311A1 Oral delivery of peptide pharmaceutical compositions |
| 01/19/2006 | CA2570121A1 Methods and compositions for modulating bax-ku70-mediated apoptosis |
| 01/19/2006 | CA2561841A1 Methods for suppressing neovascularization using ephrinb2 |
| 01/19/2006 | CA2553436A1 Peptides selectively lethal to malignant and transformed mammalian cells |
| 01/18/2006 | EP1617219A1 Element having bioactive substance fixed thereto |
| 01/18/2006 | EP1617216A1 Novel method of screening |
| 01/18/2006 | EP1616963A2 Process for producing dipeptides or dipeptide derivatives |
| 01/18/2006 | EP1616961A1 Vectors and methods for gene transfer to cells |
| 01/18/2006 | EP1616960A2 Human pancreatic cell lines: developments and uses |
| 01/18/2006 | EP1616958A2 Notch-ligands for use in immunotherapy |
| 01/18/2006 | EP1616956A1 Cell death-inducing fused gene acting specifically on cancer and gene product thereof |
| 01/18/2006 | EP1616955A1 Catalyst for sugar chain cleavage |
| 01/18/2006 | EP1616954A2 Methods and reagents for vaccination which generate a CD8 T cell immune response |
| 01/18/2006 | EP1616948A1 Thioredoxin modification |
| 01/18/2006 | EP1616883A2 Antibodies against VLA-4 |
| 01/18/2006 | EP1616878A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/18/2006 | EP1616877A1 Reagents for diagnosis and therapy of latex allergy and method for the preparation of the same |
| 01/18/2006 | EP1616875A1 GD3-mimetic peptides |
| 01/18/2006 | EP1616580A2 Alpha-amylase transcription factor |
| 01/18/2006 | EP1616579A1 CD40 binding molecules and CTL peptides for treating tumors |
| 01/18/2006 | EP1616578A1 Compositions and methods for delivery of genetic material |
| 01/18/2006 | EP1616577A1 Agent for repairing corneal perception |
| 01/18/2006 | EP1616575A1 Method for treating inflammation |
| 01/18/2006 | EP1616574A1 Receptor specific transepithelial transport of therapeutics |
| 01/18/2006 | EP1616572A1 Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody |
| 01/18/2006 | EP1616571A2 Lysine containing peptides for treatment of heart disease |
| 01/18/2006 | EP1616556A1 Compostions comprising gelatin-glycine and carotenoids |
| 01/18/2006 | EP1616190A1 Diagnosis of advanced cancer |
| 01/18/2006 | EP1616183A2 Methods of detecting neurological disorders |
| 01/18/2006 | EP1616019A2 Method for extracting collagen comprising microbial fermentation |
| 01/18/2006 | EP1616016A2 Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain |
| 01/18/2006 | EP1616010A2 Cytokine polypeptides and antibodies containing a signal sequence for the attachment of glycosylphosphatidylinositol |
| 01/18/2006 | EP1616009A2 Method for treatment of angiogenic disorders |
| 01/18/2006 | EP1616007A1 Inhibitor proteins of a protease and use thereof |
| 01/18/2006 | EP1616004A1 Process for isolating and purifing ovine hyaluronidase |
| 01/18/2006 | EP1615996A2 Uses of vascular endothelial growth factor and type i collagen inducible protein (vcip) |
| 01/18/2006 | EP1615959A2 A method for the production of emulsion-based micro particles |
| 01/18/2006 | EP1615954A2 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
| 01/18/2006 | EP1615953A2 Agent comprising an albumin-like first polypeptide bound to a second polypeptide |
| 01/18/2006 | EP1615952A2 Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2 |
| 01/18/2006 | EP1615951A2 Method for identifying an anti-streptococcal agent and its use for treating streptococcal infections |
| 01/18/2006 | EP1615676A2 Porous particulate collagen sponges |
| 01/18/2006 | EP1615675A1 A seeded tear resistant scaffold |
| 01/18/2006 | EP1615664A1 Pharmaceutical composition for treatment of immunological disorders |
| 01/18/2006 | EP1615663A1 Agent for treating leishmania infections |
| 01/18/2006 | EP1615660A1 Pharmaceutical composition containing interferon for the treatment of hpv infections |
| 01/18/2006 | EP1615659A2 Use of bv8 and/or eg-vegf to promote hematopoiesis |
| 01/18/2006 | EP1615658A1 Inhibition of tumor cell proliferation by foxm1b inhibitors |
| 01/18/2006 | EP1615657A1 Immunomodulatory product obtained from a bifidobacterium culture and compositions containing the same |
| 01/18/2006 | EP1615656A2 Immunomodulatory product obtained from a bifidobacterium culture and compositions containing the same |
| 01/18/2006 | EP1615655A1 Compositions for mucosal and oral administration comprising hcg fragments |
| 01/18/2006 | EP1615654A2 Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques |
| 01/18/2006 | EP1615653A2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| 01/18/2006 | EP1615652A2 Treatment of severe acute respiratory syndrome (sars) |
| 01/18/2006 | EP1615640A2 Antineoplastic combinations |
| 01/18/2006 | EP1615612A2 Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots |
| 01/18/2006 | EP1576153A4 Device and process for the preparation of autologous thrombin serum |
| 01/18/2006 | EP1539816B1 Thrombin-cleavable factor x analogues |
| 01/18/2006 | EP1512016B1 Screening method and anti-tumor drug candidate obtained therefrom |
| 01/18/2006 | EP1503780A4 Androgen-regulated pmepa1 gene and methods of using the same to inhibit cancer cell growth |
| 01/18/2006 | EP1404672B1 Tyrosine kinase inhibitors |
| 01/18/2006 | EP1268096B1 Extrusion die |
| 01/18/2006 | EP1252181B1 Peptides with antibacterial activity |
| 01/18/2006 | EP1232183B1 Peptides having antiangiogenic activity |
| 01/18/2006 | EP1220852B1 Substituted diazepans |
| 01/18/2006 | EP1210327B1 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments |
| 01/18/2006 | EP1200115B9 Multi-dose erythropoietin formulations |
| 01/18/2006 | EP1127068B1 Immunotherapeutic methods using epitopes of wt-1 and gata-1 |
| 01/18/2006 | EP1071442B9 Methods and compositions for peptide synthesis (t-20) |
| 01/18/2006 | EP1015483B1 Malaria polypeptides |
| 01/18/2006 | EP0998274B1 Microdose therapy of vascular conditions by no donors |
| 01/18/2006 | EP0994722B1 Method of removing endotoxin from vaccines |
| 01/18/2006 | EP0915910B1 Exendin analogues, processes for their preparation and medicaments containing them |
| 01/18/2006 | EP0815197B1 Long qt genes and method for diagnosing or preventing the occurrence of long qt syndrome |
| 01/18/2006 | EP0782630B1 Polycystic kidney disease gene |
| 01/18/2006 | EP0735895B1 A method for preventing or controlling cataract |
| 01/18/2006 | CN1723283A Method for manufacturing recombinant polyclonal proteins |
| 01/18/2006 | CN1723052A Enhanced parmacokinetic profile of hydrophobic dopamine agonists administered to the dermis |
| 01/18/2006 | CN1723041A Stable immunogenic product comprising antigenic heterocomplexes |
| 01/18/2006 | CN1723040A Amended recombinant cells (ARCs) for the production and delivery of antiviral agents, adjuvants and vaccine accelerants |
| 01/18/2006 | CN1723037A Methods and compositions for promoting the maturation of monocytes |